Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Board Changes

7 Apr 2008 07:01

TyraTech, Inc.07 April 2008 For immediate release 7 April 2008 TYRATECH INC. ("TyraTech", "the Company" or "the Group") BOARD CHANGES TyraTech Inc. (AIM: TYR), a leading independent novel pesticide company forhuman, animal and environmental health, is pleased to announce that David PaulSzostak, aged 53, will join the Board of TyraTech as a Non-Executive Directorand that Rick Brenner, aged 54, Executive Director and founding CEO of TyraTechand VP of Business Development for XL TechGroup, will step down from the Board.Rick will continue his day to day business development responsibilities atTyraTech. Both of the Board changes outlined above will take place withimmediate effect. Mr. Szostak is an Executive Director, Chief Financial Officer and CompanySecretary at XL TechGroup, Inc. (AIM: XLT), and began his career in Chicago,Illinois working as a certified public accountant (CPA) for a large sizeaccountancy firm (Laventhol and Howarth) and later other smaller accountingfirms. He then moved into industry in 1987 as corporate controller at Extel,Inc., a global manufacturer of electronic communication equipment for industryand governments. When Extel acquired Hetra Computer, Inc., a manufacturer ofgovernment specialty computers, in 1990, Mr. Szostak relocated to Florida andaccepted the position of vice president and CFO of Hetra. In 1993, when XLVision, the predecessor company to XL TechGroup, acquired Hetra, Mr. Szostakcontinued in the same position with XL Vision. During his tenure at XL Vision,he was active in both the fundraising and public offerings of the XL Visionspin-out businesses. In addition to the accounting and finance functions, Mr.Szostak was responsible for many of the internal functions such as humanresources and benefits, legal, travel and facilities. Mr. Szostak earned hisBachelor of Science in Finance at Southern Illinois University, with graduatestudies at DePaul University in Chicago. XL TechGroup have a 47.92% stake in TyraTech. Mr. Szostak's previous and current Directorships include the following:Company Name Date of DirectorshipeMerge Interactive, Inc. 1996 - 97Sanctuary HO Association 2002 - 04ANX LLC (formerly AgCert International LLC) 2002 - 03XL TechGroup LLC 2001 - 04XL TechGroup, Inc 2004- PresentXL TechGroup Employee 2007- PresentCharitable Fund, IncDxTech LLC 2005 - PresentPetroAlgae LLC 2006 - PresentGenXL LLC 2006 - Present There are no further details required to be disclosed pursuant to Schedule Two,paragraph (g) of the AIM Rules. Commenting on this announcement, Geoffrey N. Vernon, Non-Executive Chairman ofTyraTech, said: "I would like to thank Rick Brenner for his considerablecontribution to TyraTech as an Executive Board member and am delighted that hewill continue his day to day responsibilities assisting TyraTech. We welcomeDavid to the Board and look forward to working with him." For further information please contact:TyraTech Inc. +1 (321) 409 7403Douglas Armstrong Ph.D., Chief Executive Officerwww.tyratech.com Nomura Code Securities +44 (0)20 7776 1200Charles Walker/Clare Terlouwwww.nomuracode.com Buchanan Communications +44 (0) 20 7466 5000Mary-Jane Johnson mary-jane.johnson@buchanan.uk.comLisa Baderoon/Catherine Breenwww.buchanan.uk.com About TyraTech TyraTech was formed in 2004 to develop and commercialise products for thecontrol of invertebrate pests and pathogens using the Company's proprietarytechnology. TyraTech, which already has products on the market, is positionedfor human health, animal health and pesticide market opportunities which totalover $23 billion globally. TyraTech's technology provides the Company with awide variety of product and business opportunities in many markets andgeographic regions. The differentiating feature of these products is thepotential to have a combined level of potency and safety that other invertebratecontrol products are unable to offer. TyraTech's platform brings many of theprinciples of drug discovery and development to the fields of insecticides andparasiticides. By targeting specific chemoreceptors that are found ininvertebrates but not in humans and animals, TyraTech can produce products thatuse natural plant derived compounds targeting these receptors. TyraTech's plan for the use of its technology is to develop selected proprietaryactive ingredients which can then be used across a wide variety of marketsegments, either by development partners or by TyraTech itself. TyraTech alreadyhas products or partnerships in the areas of professional and horticulturalinsect control, and for an insect/mosquito repellent. TyraTech also has aninnovative partnership with Kraft to use its natural oils to develop functionalfoods for helping control of parasitic infections and diseases that affect morethan 2 billion people worldwide. TyraTech also has a separate technology with associated intellectual propertythat is the basis for the Sustainable Solutions business. This technology hasbeen incorporated into specialised dairy farm equipment for processing cattlemanure waste to a usable material for TyraTech to sell as a commercial plantgrowing medium. For more information please visit www.tyratech.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20157:00 amRNSMigration of shares
6th Aug 20157:00 amRNSMigration of Shares
30th Jul 20154:38 pmRNSResult of AGM
3rd Jul 20155:04 pmRNSMigration of Shares
22nd Jun 20157:00 amRNSFinal Results
10th Jun 20152:22 pmRNSMigration of Shares
26th May 20157:01 amRNSSmartPak launches OutSmart insect repellent
21st May 20155:45 pmRNSMigration of Shares
22nd Apr 20157:00 amRNSDirector's Dealings
20th Apr 20157:00 amRNSEnvance LLC amended: Sharpened strategic focus
9th Apr 20151:14 pmRNSMigration of Shares
8th Apr 20157:00 amRNSListing with Walgreens in the USA
27th Mar 20159:41 amRNSMigration of Shares and Exercise of SARs
25th Mar 20157:00 amRNSVamousse now distributed by CVS in the USA
3rd Mar 20157:00 amRNSVamousse now listed by the top 3 distributors, USA
25th Feb 20157:00 amRNSLloyds and Day Lewis Pharmacy listings
16th Feb 20155:01 pmRNSDirector's Dealings
2nd Feb 20157:00 amRNSVamousse at Walmart and Cardinal Health USA
26th Jan 20157:00 amRNSInnovators and Investors Forum, London
15th Jan 20157:00 amRNSAppointment of Chief Financial Officer & Treasurer
2nd Dec 20147:00 amRNSTrading Update
1st Oct 20147:00 amRNSExercise of Warrants
29th Sep 20147:00 amRNSInterim Results
27th Aug 20147:00 amRNSVamousse products coming to Sainsbury's and Tesco
8th Aug 201410:30 amRNSHolding(s) in Company
5th Aug 201410:29 amRNSHolding(s) in Company
1st Aug 20145:49 pmRNSHolding(s) in Company
1st Aug 20142:40 pmRNSHolding(s) in Company
28th Jul 20145:35 pmRNSResult of Special Meeting & Director Shareholdings
16th Jul 20147:00 amRNSResult of AGM
16th Jul 20147:00 amRNSPlacing to raise £3.5m and launch of UK Vamousse
26th Jun 20147:00 amRNSFinal Results
22nd May 20144:02 pmRNSMigration of Shares
19th May 20146:15 pmRNSMigration of Shares
19th May 20147:00 amRNSVamousse product line available online across USA
30th Apr 20147:00 amRNSNatunex product launched across USA
24th Apr 20147:00 amRNSUSA Pest Control Patents Secured
8th Apr 20146:10 pmRNSDirector's Dealings
7th Apr 20144:41 pmRNSDirector's Dealings
1st Apr 20147:00 amRNSVamousse at over 4,000 Walmart Stores in USA
7th Mar 20147:00 amRNSMigration of Shares
6th Mar 201411:48 amRNSHolding(s) in Company
6th Mar 20147:00 amRNSAward of Share Options
24th Feb 20147:00 amRNSProposed Migration of Shares
18th Feb 20143:38 pmRNSResult of Special Meeting
13th Feb 20149:47 amRNSHolding(s) in Company
31st Jan 20144:26 pmRNSProposed Placing
23rd Jan 20145:58 pmRNSHolding(s) in Company
20th Jan 20147:00 amRNSHead-Lice Preventative Shampoo Coming to US Market

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.